Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection - PubMed (original) (raw)
Clinical Trial
. 2000 Jul 15;96(2):467-74.
C M Bechtel, V Natarajan, M Baseler, K M Hege, J A Metcalf, R Stevens, A Hazen, R M Blaese, C C Chen, S F Leitman, J Palensky, J Wittes, R T Davey Jr, J Falloon, M A Polis, J A Kovacs, D F Broad, B L Levine, M R Roberts, H Masur, H C Lane
Affiliations
- PMID: 10887107
Free article
Clinical Trial
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
R E Walker et al. Blood. 2000.
Free article
Abstract
To study human immunodeficiency virus (HIV)-specific cellular immunity in vivo, we transferred syngeneic lymphocytes after ex vivo expansion and transduction with a chimeric receptor gene (CD4/CD3-zeta) between identical twins discordant for HIV infection. Single and multiple infusions of 10(10) genetically modified CD8(+) T cells resulted in peak fractions in the circulation of approximately 10(4) to 10(5) modified cells/10(6) mononuclear cells at 24 to 48 hours, followed by 2- to 3-log declines by 8 weeks. In an effort to provide longer high-level persistence of the transferred cells and possibly enhance anti-HIV activity, we administered a second series of infusions in which both CD4(+ )and CD8(+) T cells were engineered to express the chimeric receptor and were costimulated ex vivo with beads coated with anti-CD3 and anti-CD28. Sustained fractions of approximately 10(3) to 10(4) modified cells/10(6) total CD4(+) or CD8(+) cells persisted for at least 1 year. Assessment of in vivo trafficking of the transferred cells by lymphoid tissue biopsies revealed the presence of modified cells in proportions equivalent to or below those in the circulation. The cell infusions were well tolerated and were not associated with substantive immunologic or virologic changes. Thus, adoptive transfer of genetically modified HIV-antigen-specific T cells was safe. Sustained survival in the circulation was achieved when modified CD4(+ )and CD8(+) T cells were infused together after ex vivo costimulation, indicating the important role played by antigen-specific CD4(+) T cells in providing "help" to cytotoxic effectors. (Blood. 2000;96:467-474)
Similar articles
- Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.
Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. Mitsuyasu RT, et al. Blood. 2000 Aug 1;96(3):785-93. Blood. 2000. PMID: 10910888 Clinical Trial. - Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE. Price DA, et al. J Virol. 2003 May;77(10):6041-9. doi: 10.1128/jvi.77.10.6041-6049.2003. J Virol. 2003. PMID: 12719595 Free PMC article. Clinical Trial. - [Deep lung--cellular reaction to HIV].
Tavares Marques MA, Alves V, Duque V, Botelho MF. Tavares Marques MA, et al. Rev Port Pneumol. 2007 Mar-Apr;13(2):175-212. Rev Port Pneumol. 2007. PMID: 17492233 Review. Portuguese. - Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G, Yanez AG, Maus M, Walker BD. Mylvaganam G, et al. Front Immunol. 2019 Sep 10;10:2109. doi: 10.3389/fimmu.2019.02109. eCollection 2019. Front Immunol. 2019. PMID: 31552045 Free PMC article. Review.
Cited by
- Interventions during Early Infection: Opening a Window for an HIV Cure?
Hiner CR, Mueller AL, Su H, Goldstein H. Hiner CR, et al. Viruses. 2024 Oct 9;16(10):1588. doi: 10.3390/v16101588. Viruses. 2024. PMID: 39459922 Free PMC article. Review. - Applications of cell therapy in the treatment of virus-associated cancers.
Toner K, McCann CD, Bollard CM. Toner K, et al. Nat Rev Clin Oncol. 2024 Oct;21(10):709-724. doi: 10.1038/s41571-024-00930-x. Epub 2024 Aug 19. Nat Rev Clin Oncol. 2024. PMID: 39160243 Review. - Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.
Zenere G, Wu C, Midkiff CC, Johnson NM, Grice CP, Wimley WC, Kaur A, Braun SE. Zenere G, et al. PLoS One. 2024 Aug 12;19(8):e0293990. doi: 10.1371/journal.pone.0293990. eCollection 2024. PLoS One. 2024. PMID: 39133676 Free PMC article. - Generation of Anti-HIV CAR-T Cells for Preclinical Research.
Su H, Anthony-Gonda K, Orentas RJ, Dropulić B, Goldstein H. Su H, et al. Methods Mol Biol. 2024;2807:287-298. doi: 10.1007/978-1-0716-3862-0_20. Methods Mol Biol. 2024. PMID: 38743236 - Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study.
Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, Zhu L, Zhao C, Liu Q, Liu L, Chen J, Gu L, Liu Z, Pan X, Xue Y, Feng M, Ying T, Zhou P, Wu Z, Xiao J, Zhang R, Leng J, Sun Y, Zhang X, Xu J. Mao Y, et al. Cell Discov. 2024 May 14;10(1):49. doi: 10.1038/s41421-024-00658-z. Cell Discov. 2024. PMID: 38740803 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials